Patents Represented by Attorney, Agent or Law Firm Mark S. Scott
-
Patent number: 6737061Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: May 18, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6737060Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: October 31, 2001Date of Patent: May 18, 2004Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6495137Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.Type: GrantFiled: October 30, 1997Date of Patent: December 17, 2002Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu, Eduardo A. Padlan
-
Patent number: 6417337Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.Type: GrantFiled: February 18, 1998Date of Patent: July 9, 2002Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6348581Abstract: Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.Type: GrantFiled: February 18, 1998Date of Patent: February 19, 2002Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6333405Abstract: Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.Type: GrantFiled: September 28, 2000Date of Patent: December 25, 2001Assignee: The Dow Chemical CompanyInventors: W. H. Kerr Anderson, Philip R. Tempest, Frank J. Carr, William J. Harris, Kathryn Armour
-
Patent number: 6329507Abstract: The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.Type: GrantFiled: August 21, 1992Date of Patent: December 11, 2001Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Joseph A. Affholter, Nicolas J. Kotite
-
Patent number: 6207815Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49H, CC83 VH, and CC92 VH, and CC49L, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.Type: GrantFiled: June 7, 1995Date of Patent: March 27, 2001Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
-
Patent number: 6071515Abstract: The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: June 6, 2000Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Joseph A. Affholter, Nicolas J. Kotite
-
Patent number: 6051225Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.Type: GrantFiled: March 31, 1993Date of Patent: April 18, 2000Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
-
Patent number: 5993813Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.Type: GrantFiled: March 24, 1997Date of Patent: November 30, 1999Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
-
Patent number: 5976531Abstract: This invention concerns a subset of composite Hum4 V.sub.L, V.sub.H antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have variable regions with (1) V.sub.L segments derived from the human subgroup IV germline gene, and (2) a V.sub.H segment which is capable of combining with the V.sub.L to form a three dimensional structure having the ability to bind TAG-72. In vivo methods of treatment and diagnostic assay using these composite antibodies is also disclosed.Type: GrantFiled: June 16, 1994Date of Patent: November 2, 1999Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson
-
Patent number: 5976845Abstract: This invention concerns a subset of composite Hum4 V.sub.L, V.sub.H antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have variable regions with (1) V.sub.L segments derived from the human subgroup IV germline gene, and (2) a V.sub.H segment which is capable of combining with the V.sub.L to form a three dimensional structure having the ability to bind TAG-72. In vivo methods of treatment and diagnostic assay using these composite antibodies is also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: November 2, 1999Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson